Research Alliance Corp IVRACD
Cash in trust
—
Not yet disclosed
Trust per share
—
Redemption value
IPO
Jul 2026
—
Combination deadline
Jul 13, 2028
678 days remaining
Filings on record
22
Latest Aug 19, 2026
Overview
Research Alliance Corp IV is a special purpose acquisition company incorporated in Cayman Islands and registered with the SEC under CIK 0002137777. It completed its initial public offering in Jul 2026 and listing on Nasdaq. Class A shares trade under the ticker RACD on Nasdaq. The vehicle is sponsored by Research Alliance through Research Alliance Holdings IV LLC. The mandate targets healthcare. IPO closed, trust funded, no definitive agreement announced.
“we intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare or healthcare-related industries.”
Reading the filings
Arithmetic on what Research Alliance Corp IV has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.
Time on the clock
678 days to the Jul 13, 2028 deadline. The vehicle is early in its search window, and the deadline is not yet the binding constraint.
Sponsor record
Research Alliance has launched 3 vehicles. Of the 1 that have resolved, 0 closed a combination and 1 liquidated, a 0% completion rate. A sponsor's record is not a forecast, but it does tell you whether the team has taken a deal across the line before.
Scores
Recomputed 4m agoThree readings of Research Alliance Corp IV, each an unweighted mean of the components shown beneath it, and each component a percentile against every live SPAC rather than an absolute we invented. They describe the setup, not the merit. How they are built
Edge
ElevatedHow much does the structure protect a holder right now?
66/100
- Runway99
678 days
- Sponsor record33
0.0%
Edge reads the setup, not the business. A vehicle can score well on protection and still be a poor place to leave money once a deal closes.
FOMO
LowHow much attention is this vehicle attracting right now?
7/100
- Filing activity14
1 in 30 days
- News coverage0
0 stories in 30 days
Attention is not quality. FOMO rises on news volume and on the market paying above trust, both of which have preceded plenty of disappointments.
Potential
ModerateHow likely is this vehicle to complete a combination, and at what scale?
36/100
- Sponsor record33
0.0%
- Stage40
searching
Potential is about execution, not about the target. It says nothing about whether the eventual deal is worth owning, because the target is usually unknown when the score is computed.
These are derived measures, not ratings of investment merit. They carry no view on the target, no price target and no recommendation, and a high score is not a reason to buy anything.
News on Research Alliance Corp IV
Last 90 days- Research Alliance Corporation IV Prices Its SPAC IPO Of 7.5M Shares At $10.00 Per SharePositive
Benzinga · 1mo ago
News sentiment
PositiveAcross 2 recent stories, weighted towards the newest. Scored by our own headline classifier using finance- and SPAC-specific terms. It reads what a story is about, not what the shares are worth.
SEC filing history
Free tier: filings older than 24 hours- 10-Q
Quarterly report
Accession 0001193125-26-356882
- SCHEDULE 13D
Beneficial ownership report (activist)
Accession 0002137786-26-000012
- SCHEDULE 13G
Beneficial ownership report (passive)
Accession 0001493152-26-034085
- SCHEDULE 13G
Beneficial ownership report (passive)
Accession 0000921895-26-001836
- 8-K
Other events
Items 8.01, 9.01 · Accession 0001193125-26-309108
- SCHEDULE 13G
Beneficial ownership report (passive)
Accession 0001831942-26-000030
- SCHEDULE 13G
Beneficial ownership report (passive)
Accession 0001193125-26-308898
- 4
Statement of changes in beneficial ownership
Accession 0002137786-26-000010
- 4
Statement of changes in beneficial ownership
Accession 0001817056-26-000008
- 8-K
Entry into a material definitive agreement; Other events
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01 · Accession 0001193125-26-303344
- 424B4
Final IPO prospectus
Accession 0001193125-26-301373
- EFFECT
Notice of effectiveness
Accession 9999999995-26-002250
- CERT
Exchange listing certification
Accession 0001354457-26-000664
- 3
Initial statement of beneficial ownership
Accession 0002137786-26-000007
- 3
Initial statement of beneficial ownership
Accession 0002124312-26-000004
- 3
Initial statement of beneficial ownership
Accession 0001608774-26-000004
- 3
Initial statement of beneficial ownership
Accession 0001817056-26-000005
- 3
Initial statement of beneficial ownership
Accession 0002133304-26-000005
- 3
Initial statement of beneficial ownership
Accession 0001295830-26-000004
- 8-A12B
Registration of securities on an exchange
Accession 0001193125-26-300332
- S-1/A
S-1/A
Accession 0001193125-26-298633
- S-1
Registration statement for the initial public offering
Accession 0001193125-26-262052
Research Alliance Corp IV: questions answered
What is Research Alliance Corp IV (RACD)?
Research Alliance Corp IV is a special purpose acquisition company incorporated in Cayman Islands and registered with the SEC under CIK 0002137777. It completed its initial public offering in Jul 2026 and listing on Nasdaq. Class A shares trade under the ticker RACD on Nasdaq. The vehicle is sponsored by Research Alliance through Research Alliance Holdings IV LLC. The mandate targets healthcare. IPO closed, trust funded, no definitive agreement announced.
How much does Research Alliance Corp IV hold in trust?
No trust balance has been disclosed in a filing we have indexed for Research Alliance Corp IV. For a newly priced IPO this is normal: the figure first appears in the quarterly report after closing.
When must Research Alliance Corp IV complete a merger?
By Jul 13, 2028. If no combination closes by then the sponsor must seek a further extension or wind the vehicle up and return the trust.
What happens if Research Alliance Corp IV does not find a target in time?
The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.
Can I redeem shares in Research Alliance Corp IV, and at what price?
Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.
What tickers does Research Alliance Corp IV trade under?
Class A shares trade as RACD on Nasdaq. Units trade first and separate into their component securities roughly 52 days after the IPO; only the Class A shares carry the redemption right against the trust.
Is the trust value the same as the share price for Research Alliance Corp IV?
No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.
Who sponsors Research Alliance Corp IV, and what is their track record?
Research Alliance Holdings IV LLC is the sponsor entity, part of the Research Alliance franchise. That franchise has launched 3 vehicles in total, of which 0 closed a combination and 1 liquidated, a 0% completion rate on resolved vehicles.
Is Research Alliance Corp IV tradeable, and where?
Yes. RACD returned a live quote of $12.51 on Nasdaq. Quotes here are delayed and refreshed on a schedule rather than streamed, so treat the figure as indicative and confirm on your own venue. Units and warrants trade under their own symbols and are quoted separately.
Is Research Alliance Corp IV a good investment?
That is not a question this site answers. Research Alliance Corp IV is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.
Where does this Research Alliance Corp IV data come from?
Filings Research Alliance Corp IV submitted to the SEC under CIK 0002137777: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.
Compiled by the SPACListing research desk
Last reconciled Sep 4, 2026
Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.
Read the full methodology · What is in the dataset · Report a correction
SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.
Continue reading
The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.
Research Alliance: the full record
Every vehicle this sponsor has launched, what closed, what liquidated and what is still live.
Healthcare SPACs
Every vehicle chasing the same mandate, ranked by cash in trust.
All spacs searching for a target
IPO closed, trust funded, no definitive agreement announced.
Deadline calendar
Which sponsors are running out of time, and when the extension votes land.
What is a SPAC?
The structure, the economics and where the risks actually sit.
SPAC glossary
Every term in a blank-check filing, defined the way practitioners use it.
How this data is built
Coverage universe, ingestion, normalisation, lifecycle classification and known limits.